Posted: 4 month(s) ago   |   1 Comment(s)   |   Rating: 0 0
Posted by: In_The_News

Earlier this week the Chilean Institute of Public Health (ISP; http://www.ispch.cl) issued the Registration Certificate for Mellow Hope's H1N1 Influenza A Vaccine (Virion Split) The government tenders the bid in the scope of 4 to 6 million doses and had already secured the first order of 200,000 doses. This vaccine, worth approximately $1.8 million USD, will ship to the Chilean private market

HTDS' CEO Terry Yuan said "The Government of Chile showed a great agility in the fight against the H1N1. The Government does everything in its power to assure the safety of Chilean citizens and the vaccine negotiations had been exemplary ones." Mr. Yuan said further "Yes, the first 200,000 doses had been scheduled, but the final number tendered by the government is somewhere between 4 to 6 million doses. The final figures still need be worked out with the Chilean health authorities, but this is a tremendous start to our South American Expansion and we are looking forward to work with other governments in this region."

Hard to Treat Diseases (HTDS) operates two medical subsidiaries in Europe and Mainland China. HTDS is a parent company with operations in East European Serbia based pharmaceutical company Slavica Bio Chem Co and in China Mellow Hope Inc.

To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates.

Safe Harbor Statement:
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters, www.minamargroup.com

Member Rating: 0 0